MindMed gains after investigator trial of LSD shows impact on major depression
Shares of MindMed surged Friday morning after researchers who have worked with the company unveiled positive results in a trial using LSD to treat major depressive disorder, running a test similar to the biotech’s trials of its own related compound.
The Swiss investigators at the University Hospital Basel and the University Hospital of Psychiatry treated 28 patients with a high dose of LSD, while 27 patients received a much lower active control dose. Patients were measured using the Inventory of Depressive Symptomatology system, which scores depression based on a score of zero to 84.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.